COVID-19 IMPACT SURVEY MAY 2020
Amid the COVID-19 crisis and the looming economic recession, the Ulcerative Colitis Therapeutics market worldwide will grow by a projected US$2.3 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 5.1%. Ulcerative Proctitis, one of the segments analyzed and sized in this study, is forecast to grow at over 4.7% and reach a market size of US$2.1 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Ulcerative Proctitis market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.
As part of the new emerging geographic scenario, the United States is forecast to readjust to a 6.1% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$109.2 Million to the region's size over the next 7 to 8 years. In addition, over US$103.3 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Ulcerative Proctitis segment will reach a market size of US$197.9 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Ulcerative Colitis Therapeutics market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 5.5% over the next couple of years and add approximately US$402.9 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Ulcerative Colitis Therapeutics market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include, among others, Abbott Laboratories, Inc.; AbbVie, Inc.; Amgen, Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma, Inc.; AstraZeneca PLC; Avaxia Biologics, Inc.; BioLineRx Ltd.; Celgene Corporation; Cosmo Pharmaceuticals NV; EA Pharma Co., Ltd.; Eisai Co., Ltd.; Ferring Pharmaceuticals; Galapagos NV; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Hutchison MediPharma Limited; Immune Pharmaceuticals, Inc.; InDex Pharmaceuticals Holding AB; Janssen Biotech, Inc.; Kaken Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Co., Ltd.; Lipid Therapeutics GmbH; Meda AB; Merck & Co., Inc.; Mitsubishi Tanabe Pharma Corporation; Mochida Pharmaceutical Co., Ltd.; Morphotek, Inc.; Nestle SA; Pfizer, Inc.; Procter & Gamble Company, The; Qu Biologics Inc.; Salix Pharmaceuticals, Inc.; Shield Therapeutics PLC; Shire Pharmaceuticals, Inc.; Sterna Biologicals GmbH & Co. KG; Takeda Pharmaceuticals Company Ltd.; Tillotts Pharma AG; TopiVert Ltd.; UCB SA; Zeria Pharmaceutical Co., Ltd.